文献速递糖尿病

1型糖尿病患者急性胰岛素撤除及酮症酸中毒发生期间SGLT2抑制剂达格列净的代谢效应

Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2020-07-08

本研究为双盲、安慰剂对照交叉试验,12例使用胰岛素泵的1型糖尿病患者随机接受达格列净或安慰剂7天,洗脱期4周。在胰岛素撤除期间,达格列净组终点血糖显著低于安慰剂组,β-羟丁酸AUC0-180 min显著更高,甘油Ra AUC0-180 min小幅但显著升高,非酯化脂肪酸无差异。作者认为达格列净使β-羟丁酸升高可能部分源于脂解增加。

要点

  • 达格列净组胰岛素撤除后终点血糖显著低于安慰剂组。
  • 达格列净组β-羟丁酸AUC0-180 min显著高于安慰剂组。
  • 达格列净组甘油Ra AUC0-180 min小幅但显著升高,非酯化脂肪酸无差异。

核心结论

  • 胰岛素撤除期间,达格列净使β-羟丁酸升高可能部分由于脂解增加,但肾脏排泄减少、外周组织β-羟丁酸摄取减少或肝脏生酮增加也可能起作用。

研究设计与样本

  • 双盲、安慰剂对照交叉研究,洗脱期4周,纳入12例使用胰岛素泵治疗的1型糖尿病患者,随机顺序接受达格列净或安慰剂7天,输注稳定同位素测定葡萄糖Ra、Rd和脂解。

主要发现

  • 基线时达格列净组葡萄糖Ra显著高于安慰剂组。
  • 胰岛素撤除后,达格列净组终点血浆葡萄糖浓度显著低于安慰剂组。
  • 达格列净组葡萄糖Rd AUC0-180 min和β-羟丁酸(BOHB)AUC0-180 min显著高于安慰剂组。
  • 达格列净组甘油Ra(脂解指标)AUC0-180 min小幅但显著高于安慰剂组。
  • 非酯化脂肪酸浓度两组间无差异;按BMI>27和<27 kg/m2分层后,低BMI组中达格列净治疗者的基础葡萄糖Ra、BOHB和甘油Ra AUC0-180 min显著高于低BMI组安慰剂治疗者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on glucose flux, lipolysis, and ketone body concentrations during insulin withdrawal in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: A double-blind, placebo-controlled crossover study with a 4-week washout period was performed in 12 people with type 1 diabetes using insulin pump therapy. Participants received dapagliflozin or placebo in random order for 7 days. Stable isotopes were infused to measure the glucose Ra, Rd, and lipolysis. At isotopic steady state, insulin was withdrawn, and the study was terminated after 600 min or earlier if blood glucose reached 18 mmol/L, bicarbonate <15 mmol/L, venous pH <7.35, or capillary ketones >5.0 mmol/L. RESULTS: At baseline, glucose Ra was significantly higher for the dapagliflozin group than the placebo group. Following insulin withdrawal, plasma glucose concentrations at the end point were significantly lower with dapagliflozin than placebo and glucose Rd area under the curve (AUC)0-180 min and β-hydroxybutyrate (BOHB) AUC0-180 min were significantly higher. There was a small but significantly higher glycerol Ra (measure of lipolysis) AUC0-180 min with dapagliflozin. Nonesterified fatty acid concentrations were not different between treatments. When divided by BMI >27 and <27 kg/m2, basal glucose Ra, BOHB, and glycerol Ra AUC0-180 min were significantly higher in the low-BMI group with dapagliflozin treatment versus the low-BMI group with placebo. CONCLUSIONS: During insulin withdrawal, the increase in BOHB with dapagliflozin may be partially due to increased lipolysis. However, reduced renal excretion, reduced BOHB uptake by peripheral tissues, or a metabolic switch to increased ketogenesis within the liver may also play a role.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Herring RA, Shojaee-Moradie F, Garesse R, et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care. 2020. PMID: 32641376. doi:10.2337/dc19-2579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。